Journal of Yeungnam Medical Science

Original article

Performance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study: Soojoung Yu, Hwa Yeon Sun, Byungwook Yoo; J Yeungnam Med Sci. 2023;40(Suppl):S73-S80. Published online October 20, 2023; DOI: https://doi.org/10.12701/jyms.2023.00528

813 View
30 Download

Abstract PDF Supplementary Material: Background
The quick and easy nature of point-of-care (POC) testing devices allows regular monitoring of serum lipid levels to increase efficiency. The purpose of this study was to assess a POC lipid analyzer, Barozen Lipid Plus (MICO Biomed Co., Ltd.), which uses capillary blood to measure total cholesterol (TC), triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C).
Methods
Capillary and venous blood samples were collected from 110 participants at a single center in Korea between June 10 and June 26, 2021. TC, TG, and HDL-C measurements using Barozen Lipid Plus were compared with measurements using our reference device, the Roche-Hitachi Cobas 8000 c702 (Hitachi High-Technologies Corporation). This study followed the guidelines of the Clinical and Laboratory Standards Institute and the Clinical Laboratory Improvement Amendments. We surveyed participants regarding the convenience of the POC device using a questionnaire following the completion of blood collection.
Results
When compared to the reference equipment, the measurements obtained using Barozen Lipid Plus were more than 95% satisfactory within TC±10%, TG±25%, and HDL-C±30%. The coefficient of variation in the repeatability testing was within 5% for TC, 5% for TGs, and 7% for HDL-C. The survey results indicated high levels of satisfaction. No adverse events were reported.
Conclusion
These findings suggest that Barozen Lipid Plus is reliable for measuring lipid profiles and can therefore be used to monitor lipid levels at the time and place of patient care.

Case Report

Surgical treatment of recurrent pseudochylothorax occurring after therapy of tuberculous pleurisy.: Jae Ryung Yi, Woo Sik Kim, Eun Jung Jeong, Yu Na Jung, Hee Sook Lee, Gi Ho Jo, Ji Yeon Lee; Yeungnam Univ J Med. 2014;31(1):65-68. Published online June 30, 2014; DOI: https://doi.org/10.12701/yujm.2014.31.1.65

1,660 View
4 Download

Abstract PDF: Pseudochylothorax is an uncommon pleural effusion disease characterized by the presence of cholesterol crystals or high lipid content not resulting from a disrupted thoracic duct. Most of the cases reported so far had been found in patients with long-standing pleural effusion due to a chronic inflammatory disease such as old tuberculous pleurisy or chronic rheumatoid pleurisy. Authors encountered a case of pseudochylothorax in a 45-year-old man who had been treated for tuberculous pleurisy 6 years before his visit to authors' hospital. After that, he had visited the emergency department many times for removal of pleural effusion. The patient's chest X-ray revealed dyspnea and large left-sided pleural effusion. Although a large amount of pleural fluid was removed with a drainage catheter, massive pleural effusion was likely to recur, and the underlying lung was able to fully re-expand. Accordingly, decortication was done, and the patient's symptom was improved without postoperative complications.

First
Prev
Page of 1
Next
Last

Search